Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03696212
Title Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Arrys Therapeutics
Indications

lung adenocarcinoma

Therapies

Grapiprant + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST